A second confirmatory Phase III trial of RP-G28 to evaluate the efficacy, safety and durability of RP-G28 compared to a placebo in subjects with lactose intolerance.

Trial Profile

A second confirmatory Phase III trial of RP-G28 to evaluate the efficacy, safety and durability of RP-G28 compared to a placebo in subjects with lactose intolerance.

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Registrational; Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2017 According to a Ritter Pharmaceuticals media release, the company raises $23 million to fund initiation of its Phase 3 clinical program in lactose intolerance.
    • 22 Aug 2017 New trial record
    • 18 Aug 2017 According to a Ritter Pharmaceuticals media release, the company anticipates the initiation of the trial in the first half of 2018 and plans to ultimately file a successful NDA and commercialize RP-G28 as the first FDA-approved treatment for lactose intolerance.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top